Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 2, 2002, Pages 85-94

  Gandhi, Varsha ^a   Chen, Wei ^a   Ayres, Mary ^a   Rhie, Julie K ^a,b   Madden, Timothy L ^a   Newman, Robert A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

8 chloro adenosine; 8 chloro cAMP; Adenosine deaminase; Pharmacokinetics

Indexed keywords

8 CHLOROADENINE; 8 CHLOROADENOSINE; 8 CHLOROADENOSINE TRIPHOSPHATE; 8 CHLOROINOSINE; ADENOSINE DEAMINASE INHIBITOR; ADENOSINE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; PENTOSTATIN; PERCHLORIC ACID; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG METABOLISM; DRUG STABILITY; EXTRACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MONONUCLEAR CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; VALIDATION PROCESS;

2-CHLOROADENOSINE; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; INOSINE; LEUKOCYTES, MONONUCLEAR; MALE; MICE; PENTOSTATIN; PHOSPHORYLATION; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 0036351119     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0456-0     Document Type: Article

References (46)

1. Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth
2. Inhibition of growth and modulation of gene expression in human lung carcinoma and athymic mice by site selective 8-Cl-cyclic adenosine monophosphate
3. Commentary: Site-selective 8-chlorocyclic adenosine 3′,5″-monophosphate as a biologic modulator of cancer: Restoration of normal control mechanisms
4. 8-Cl-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation
5. Cooperative effect of 8-Cl-cANT and rGM-CSF on the differentiation of HL-60 human leukemia cells
6. Inhibition of colon tumor cell growth by 8-chlorocAMP dependent upon its conversion to 8-chloro-adenosine
7. Pharmacokinetics, metabolism, and tumour disposition of 8-chloroade-nosine 3′,5′-monophosphate in breast cancer patients and xenograft bearing mice
8. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients
9. 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-AD
10. 8-Chloro-cAMP and 8-chloro-adenosine act by same mechanism in multiple myeloma cells
11. 8-Cl-adenosine is an active metabolite of 8-Cl-cAMP responsible for its in vitro antiproliferative effects on CHO mutants hypersensitive to cytostatic drugs
12. 8-Chloroadenosine 3′,5′-monophosphate inhibits the growth of Chinese Hamster Ovary and Molt-4 cells through its adenosine metabolite
13. 8-Chloro-cyclic adenosine monophosphate, a novel cyclic AMP analog that inhibits human glioma cell growth in concentrations that do not induce differentiation
14. Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3′,5′-monophosphate
15. Enzymes involved in purine metabolism - A review of histochemical localization and functional implications
16. Developmental expression of adenosine deaminase in placental tissues of the early postimplantation mouse embryo and uterine stroma
17. Determination of pharmacokinetics of 8-chloroadenosine and its two major metabolites in dogs by high-performance liquid chromatography
18. Tight binding inhibitors IV Inhibition of adenosine deaminase by various inhibitors
19. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-pressure liquid chromatography
20. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells
21. Metabolism and metabolic effects of halopurine nucleosides in tumor cells in culture
22. Nucleotide specificity of human deoxycytidine kinase
23. Comparison of the Mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-D-ribofuranosyl)adenine in CEM cells
24. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity
25. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs
26. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy
27. Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells
28. Distribution of purine ribonucleoside kinase and selective toxicity of 6-methyl thiopurine ribonucleoside
29. Levels of nucleoside and nucleotide kinases in rhesus monkey tissues
30. On the pharmacokinetics of 2-chlorodeoxyadenosine in humans
31. The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA)
32. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine
33. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: Incorporation into DNA is a necessary step
34. Human erythrocyte nucleoside phosphorylase: Molecular weight and physical properties
35. Phosphorolytic cleavage of 2-fluoroadenine from 9-β-D-arabinofuanosyl-2-fluoroadenine by Escherichia coli
36. The clinical pharmacokinetics of cladribine
37. Enhancement of the antitumor activity of arabinofuranosyladenine of 2′-deoxycoformycin
38. Metabolism and action of purine nucleoside analogues
39. Specificity of adenosine deaminase inhibitors
40. Potent inhibition of muscle 5′-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin
41. Renal handling of 2′-deoxyadenosine and adenosine in humans and mice
42. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency
43. Overproduction of adenine deoxynucleotides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease
44. Adenosine-mediated killing of cultured epithelial cancer cells
45. Substrate inhibition of adenosine phosphorylation in adenosine deaminase deficiency and adenosine-mediated inhibition of PP-ribose-P dependent nucleotide synthesis in hypoxanthine phosphoribosyl deficient erythrocytes
46. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity